Half-year report 2026
High-precision delivery
medmix designs, develops, manufactures and delivers innovative high-precision devices and services for the mixing, application and injection of liquids in a wide range of viscosities for the healthcare, consumer and industrial end-markets. medmix shares are listed and traded on the SIX Swiss Exchange in Zurich (Securities No. 112.967.710/ISIN CH1129677105).
Read more about medmix here
Letter to the shareholders
Our KEY Figures
CHF214.4m
revenue in H1 2026
20.3%
adjusted EBITDA margin
CHF12.0m
free cash flow generated in H1 2026
Financial and business review
Financial reporting
